Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CAR-T cell therapy for ALL: Current challenges and future approaches

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 528

Dr Sara Ghorashian - University College London, London, UK

Dr Sara Ghorashian speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the current challenges in the field of CAR-T cell therapy.

She describes the CARPALL study, which uses a different type of CAR-T cell that signals at a lower affinity for CD-19 which has a more favourable toxicity profile in both the adult and paediatric settings.

Dr Ghorashian also discusses CAR-T cell persistence and how the therapeutic effects can disappear in a minority of patients.

She states that access to CAR-T cell therapy is limited due to its associated costs, but these can be mitigated if the therapy is administered in an ambulatory setting.


Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation